menu search

MORF / Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates

Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates
Morphic Holding, Inc. (MORF) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.85 per share a year ago. Read More
Posted: Apr 25 2023, 09:53
Author Name: Zacks Investment Research
Views: 103037

MORF News  

Morphic Holding: The Price Drop Is Very Interesting

By Seeking Alpha
September 28, 2023

Morphic Holding: The Price Drop Is Very Interesting

Morphic Holding, Inc.'s stock has dropped 61% in just 2 months, calling into question its $3bn valuation. The company's lead asset, MORF-057, targets more_horizontal

Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023

By GlobeNewsWire
September 22, 2023

Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023

-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures- more_horizontal

Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 3, 2023

Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates

Morphic Holding, Inc. (MORF) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares t more_horizontal

Morphic: High Valuation Not Justified By Data, Development Status, Or Cash

By Seeking Alpha
July 10, 2023

Morphic: High Valuation Not Justified By Data, Development Status, Or Cash

Morphic Holding, Inc. is progressing with its trials nicely enough. I just have a problem with the nearly $3bn valuation for this phase 2 stage compan more_horizontal

3 Biotech Buyout Targets to Watch

By The Motley Fool
April 29, 2023

3 Biotech Buyout Targets to Watch

89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its lead therapy this year. more_horizontal

Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023

By Seeking Alpha
April 25, 2023

Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023

Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023. more_horizontal

Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates

By Zacks Investment Research
April 25, 2023

Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates

Morphic Holding, Inc. (MORF) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares t more_horizontal

Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?

By Zacks Investment Research
April 18, 2023

Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?

Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings esti more_horizontal


Search within

Pages Search Results: